Modern Diagnostics

Modern Approach

  • Medical checkup and history review;

  • Digital mammography;

  • High-resolution ultrasound examination of breast;

  • Biopsy under ultrasound or CT;

  • Minimally invasive diagnostics (stereotactic vacuum biopsy);

  • Radioisotope examination (scintigraphy);

  • Ultrasound examination of breast;

  • Computed tomography (CT);

  • Magnetic resonance imaging (MRI);

  • Study of tumor markers of blood;

  • Second opinion in disputable cases by specialists from Germany and Singapore.




Mammography is often referred to as the golden standard in the diagnosis of breast tumors. It is the main method for diagnosis of breast diseases. It allows physicians to detect tumors of just a few millimeters in diameter.

INNOVACIA Cancer Center is equipped with M-IV Mammography System, a medical equipment of the last generation, manufactured by the U.S.-based Hologic Lorad.

The benefits of mammography conducted by INNOVACIA Cancer Center:

  • Safety: Hologic Lorad M-IV allows a study with a radiation dose reduced by 30%, if compared to conventional mammography systems.

  • High Accuracy: Hologic Lorad M-IV is equipped with an innovative HTC-Grid which provides images of high contrast due to greater absorption of scattered radiation and full transition of the direct radiation. This enables the physician to detect the least deviations of the normal condition, which obviously improves the accuracy of the examination.

  • Maximum Comfort for Patients: Hologic Lorad M-IV has no restrictions on the size of the breast, so each patient goes through with maximum comfort.

  • Convenience of Data Storage: patients can obtain the research results on a film and/or in a digital file.





For the breast ducts disease diagnosis, INNOVACIA Cancer Center uses ductography, one of the most informative methods of X-ray examination. The distinctive feature of this method is the use of contract medium in the breast ducts for two-dimensional mammography. Such study provides for an accurate diagnosis of pathological changes in the breast ducts, including, but not limited to, intraductal papillomas, ductular ectasia, adenomas. It also determines the nature and location of such pathologies.

Prior to ductography, it is required to conduct an examination of the nipple discharge. Cancer suspicion or acute inflammatory process forbids ductography. There are no age limitations for ductography; nullipara, parous women and women in menopause can be examined. 







Ultrasound of the Breast

Ultrasound of the Breast

Ultrasound is one of the principal methods of breast disease examination. The use of ultrasonic diagnostic method (ultrasound) allows detecting pathologies in breasts at their early stages. It is recommended for every woman over 20 years of age to take an ultrasound examination of breast once in 6 months.

INNOVACIA Cancer Center uses multipurpose expert class U.S.-manufactured Ultrasound Diagnostic System SenoSonix for high-accuracy diseases diagnosis. It is a world’s first equipment combining the multipurpose ultrasound scanning system functions and vacuum assisted breast needle aspiration biopsy device with 3D visualization function. The option of results recording on CD is offered.









Biopsy is a process of taking tumor tissue specimen for histological and/or immunohistological study. The objective is to detect benign or malignant processes. There are surgical and non-surgical methods of biopsy of breast tumors.

In INNOVACIA Cancer Center, all pathological studies are conducted in a histology laboratory equipped to international standards. It is a pathological research that allows determining the presence or absence of cancer. The removed (during biopsy) tissue samples are immediately examined by morphological pathology specialists.

Cancer Markers

Tumor markers are products of tumor metabolism that are released into the bloodstream. They are detected using special test systems. The detection of tumor markers is needed for (1) tumor process screening and (2) early detection of tumor recurrence after radical treatment was carried out and before the symptoms become evident.

The cancer marker research is conducted in the diagnostic laboratory of INNOVACIA Cancer Center. The laboratory is fully set to obtain the most accurate test results in the shortest possible time period. The lab receives blood and tissue samples every day. The trial results (in a form of authorized reports) are made available to physicians and patients no later than in 24 hours. The Clinic also offers other means of data transfer for the convenience of patients.

Determination of Receptors for Estrogen and Progesterone ER, PR, HER2/neu, KI-67

This is what is known as immunohistochemical study. The subject of study is a tumor specimen, specifically processed and preserved in paraffin. Immunohistochemical studies are conducted in the INNOVACIA Cancer Center Lab. It allows to research the histogenesis of the tumor, localize its primary lesion and to determine the sensitivity of tumor tissue to hormonal and chemotherapeutic drugs. This provides a solid background for development of a treatment plan and evaluation of the risk of disease recurrence.

FISH Test (Fluorescence in Situ Hybridization)

The so-called “FISH test” is a genetic examination of the tumor tissue. Specifically processed and fixed in paraffin tumor tissues are a subject of study. The test is conducted in case of doubts in the results of immunohistochemical studies. In other words, this test can be used for visualization of specific genes or their parts. The test provides “cancer-positive” or “cancer-negative” results.

MRI of the Breast

MRI of the Breast

Magnetic Resonance Imaging (MRI) is used as an additional method for the diagnosis of malignant tumors of the breast.

Magnetic Resonance Imaging (MRI) enables to define structural and functional changes in breast that is critically important for the diagnosis of breast cancer at early stages.INNOVACIA Cancer Center uses open type Magnetic Resonance Tomography Scanner which eliminates radiation exposure.








Ліцензія АЕ 459319 від 27.08.2014 видана МОЗ України

Javascript log